Nuvalent, Inc. Insider Trading

NUVL

Last 12 months

Insiders sold $125M and bought nothing on the open market.

43% of the selling was scheduled in advance under 10b5-1 plans. Director James E Flynn sold $70.9M on Nov 24, 2025 outside a plan. The last open-market buy by an executive or director was in Nov 2022.

Net open-market

−$125M

0 buys · 40 sales

Under a 10b5-1 plan

43%

of the value sold

Insiders who bought / sold

0 / 8

executives and directors

Last open-market buy

Nov 2022

Nov 3, 2022

Get an email when NUVL's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

Date	Insider	Trade	Shares	Price	Value	Of their stake	Filing
Jul 9	Henry E. Pelish Chief Scientific Officer	Sold10b5-1 plan	2,111	$123.81	261K	3.2%	Form 4
Jul 6	James Richard Porter President and CEO	Sold10b5-1 plan	30,000	$123.72	$3.71M	8.5%	Form 4
Jul 1	Darlene Noci Chief Development Officer	Sold10b5-1 plan	23,000	$123.59	$2.84M	28%	Form 4
Jul 1	Alexandra Balcom Chief Financial Officer	Sold10b5-1 plan	11,430	$123.58	$1.41M	12%	Form 4
Jun 29	Darlene Noci Chief Development Officer	Sold10b5-1 plan	5,500	$123.51	679K	8.6%	Form 4
Jun 9	Darlene Noci Chief Development Officer	Sold10b5-1 plan	20,000	$122.81	$2.46M	26%	Form 4
Jun 8	James Richard Porter President and CEO	Sold10b5-1 plan 3 parts	30,000	$88.53 average	$2.66M	8.5%	Form 4
Jun 1	Alexandra Balcom Chief Financial Officer	Sold10b5-1 plan 8 parts	11,430	$98.69 average	$1.13M	12%	Form 4
May 28	Deborah Ann Miller Chief Legal Officer	Sold10b5-1 plan 4 parts	5,500	$107.84 average	593K	8.4%	Form 4
May 28	Darlene Noci Chief Development Officer	Sold10b5-1 plan 5 parts	5,500	$107.80 average	593K	8.6%	Form 4
May 4	James Richard Porter President and CEO	Sold10b5-1 plan 5 parts	30,000	$101.69 average	$3.05M	8.5%	Form 4
May 1	Alexandra Balcom Chief Financial Officer	Sold10b5-1 plan 3 parts	11,430	$99.00 average	$1.13M	12%	Form 4
Apr 30	Deborah Ann Miller Chief Legal Officer	Sold10b5-1 plan 2 parts	5,500	$99.22 average	546K	8.4%	Form 4
Apr 29	Darlene Noci Chief Development Officer	Sold10b5-1 plan 3 parts	5,500	$99.55 average	548K	8.6%	Form 4
Apr 9	Henry E. Pelish Chief Scientific Officer	Sold10b5-1 plan 2 parts	3,093	$104.48 average	323K	4.5%	Form 4
Apr 6	James Richard Porter President and CEO	Sold10b5-1 plan 4 parts	30,000	$103.77 average	$3.11M	8.5%	Form 4
Apr 1	Alexandra Balcom Chief Financial Officer	Sold10b5-1 plan 3 parts	11,430	$105.21 average	$1.2M	12%	Form 4
Mar 30	Darlene Noci Chief Development Officer	Sold10b5-1 plan 2 parts	5,500	$97.81 average	538K	8.6%	Form 4
Mar 26	Deborah Ann Miller Chief Legal Officer	Sold10b5-1 plan 3 parts	5,500	$98.73 average	543K	8.4%	Form 4
Mar 24 – 25	Alexandra Balcom Chief Financial Officer	Sold10b5-1 plan 4 parts	25,130	$98.15 average	$2.47M	23%	Form 4
Mar 12 – 13	Henry E. Pelish Chief Scientific Officer	Sold10b5-1 plan 6 parts	35,104	$98.08 average	$3.44M	35%	Form 4
Mar 6	James Richard Porter President and CEO	Sold10b5-1 plan 3 parts	30,000	$98.99 average	$2.97M	8.5%	Form 4
Feb 26	Darlene Noci Chief Development Officer	Sold10b5-1 plan 3 parts	5,500	$103.03 average	567K	8.6%	Form 4
Feb 26	Deborah Ann Miller Chief Legal Officer	Sold10b5-1 plan 3 parts	5,500	$103.05 average	567K	8.4%	Form 4
Jan 29	Darlene Noci Chief Development Officer	Sold10b5-1 plan 4 parts	5,500	$102.08 average	561K	8.6%	Form 4
Jan 21 – 22	Deborah Ann Miller Chief Legal Officer	Sold10b5-1 plan 2 parts	15,000	$110.15 average	$1.65M	20%	Form 4
Jan 5 – 6	Henry E. Pelish Chief Scientific Officer	Sold10b5-1 plan 7 parts	5,160	$97.24 average	502K	5.8%	Form 4
Jan 5 – 6	Darlene Noci Chief Development Officer	Sold10b5-1 plan 7 parts	7,417	$97.25 average	721K	11%	Form 4
Jan 5 – 6	Deborah Ann Miller Chief Legal Officer	Sold10b5-1 plan 7 parts	6,952	$97.26 average	676K	10%	Form 4
Jan 5 – 6	Christopher Durant Turner Chief Medical Officer	Sold10b5-1 plan 7 parts	7,417	$97.25 average	721K	9.3%	Form 4
Jan 5 – 6	Alexandra Balcom Chief Financial Officer	Sold10b5-1 plan 7 parts	7,417	$97.25 average	721K	7.0%	Form 4
Jan 5 – 6	James Richard Porter President and CEO	Sold10b5-1 plan 7 parts	27,433	$97.26 average	$2.67M	7.8%	Form 4
Jan 2	Deborah Ann Miller Chief Legal Officer	Sold10b5-1 plan 3 parts	10,000	$100.51 average	$1.01M	17%	Form 4
Dec 30, 2025	Darlene Noci Chief Development Officer	Sold10b5-1 plan 2 parts	4,000	$100.04 average	400K	7.7%	Form 4
Dec 8, 2025	Alexandra Balcom Chief Financial Officer	Sold10b5-1 plan 2 parts	7,084	$110.32 average	782K	11%	Form 4
Nov 28, 2025	Darlene Noci Chief Development Officer	Sold10b5-1 plan 2 parts	4,000	$108.58 average	434K	7.7%	Form 4
Nov 24, 2025	Matthew Shair Director	Sold10b5-1 plan 8 parts	7,500	$109.37 average	820K	0.4%	Form 4
Nov 24, 2025	James E Flynn Director	SoldNo plan 2 parts	742,574	$95.45 average	$70.9M	4.1%	Form 4
Nov 17, 2025 – Nov 18, 2025	Alexandra Balcom Chief Financial Officer	Sold10b5-1 plan 8 parts	20,729	$99.62 average	$2.07M	25%	Form 4
Nov 17, 2025	Deborah Ann Miller Chief Legal Officer	Sold10b5-1 plan 3 parts	24,200	$105.50 average	$2.55M	33%	Form 4

Jul 910b5-1 plan
Henry E. Pelish
Chief Scientific Officer · sold 2,111 at $123.81
261K
3.2% of stake
Jul 610b5-1 plan
James Richard Porter
President and CEO · sold 30,000 at $123.72
$3.71M
8.5% of stake
Jul 110b5-1 plan
Darlene Noci
Chief Development Officer · sold 23,000 at $123.59
$2.84M
28% of stake
Jul 110b5-1 plan
Alexandra Balcom
Chief Financial Officer · sold 11,430 at $123.58
$1.41M
12% of stake
Jun 2910b5-1 plan
Darlene Noci
Chief Development Officer · sold 5,500 at $123.51
679K
8.6% of stake
Jun 910b5-1 plan
Darlene Noci
Chief Development Officer · sold 20,000 at $122.81
$2.46M
26% of stake
Jun 810b5-1 plan
James Richard Porter
President and CEO · sold 30,000 at avg $88.53
$2.66M
8.5% of stake
Jun 110b5-1 plan
Alexandra Balcom
Chief Financial Officer · sold 11,430 at avg $98.69
$1.13M
12% of stake
May 2810b5-1 plan
Deborah Ann Miller
Chief Legal Officer · sold 5,500 at avg $107.84
593K
8.4% of stake
May 2810b5-1 plan
Darlene Noci
Chief Development Officer · sold 5,500 at avg $107.80
593K
8.6% of stake
May 410b5-1 plan
James Richard Porter
President and CEO · sold 30,000 at avg $101.69
$3.05M
8.5% of stake
May 110b5-1 plan
Alexandra Balcom
Chief Financial Officer · sold 11,430 at avg $99.00
$1.13M
12% of stake
Apr 3010b5-1 plan
Deborah Ann Miller
Chief Legal Officer · sold 5,500 at avg $99.22
546K
8.4% of stake
Apr 2910b5-1 plan
Darlene Noci
Chief Development Officer · sold 5,500 at avg $99.55
548K
8.6% of stake
Apr 910b5-1 plan
Henry E. Pelish
Chief Scientific Officer · sold 3,093 at avg $104.48
323K
4.5% of stake
Apr 610b5-1 plan
James Richard Porter
President and CEO · sold 30,000 at avg $103.77
$3.11M
8.5% of stake
Apr 110b5-1 plan
Alexandra Balcom
Chief Financial Officer · sold 11,430 at avg $105.21
$1.2M
12% of stake
Mar 3010b5-1 plan
Darlene Noci
Chief Development Officer · sold 5,500 at avg $97.81
538K
8.6% of stake
Mar 2610b5-1 plan
Deborah Ann Miller
Chief Legal Officer · sold 5,500 at avg $98.73
543K
8.4% of stake
Mar 24 – 2510b5-1 plan
Alexandra Balcom
Chief Financial Officer · sold 25,130 at avg $98.15
$2.47M
23% of stake
Mar 12 – 1310b5-1 plan
Henry E. Pelish
Chief Scientific Officer · sold 35,104 at avg $98.08
$3.44M
35% of stake
Mar 610b5-1 plan
James Richard Porter
President and CEO · sold 30,000 at avg $98.99
$2.97M
8.5% of stake
Feb 2610b5-1 plan
Darlene Noci
Chief Development Officer · sold 5,500 at avg $103.03
567K
8.6% of stake
Feb 2610b5-1 plan
Deborah Ann Miller
Chief Legal Officer · sold 5,500 at avg $103.05
567K
8.4% of stake
Jan 2910b5-1 plan
Darlene Noci
Chief Development Officer · sold 5,500 at avg $102.08
561K
8.6% of stake
Jan 21 – 2210b5-1 plan
Deborah Ann Miller
Chief Legal Officer · sold 15,000 at avg $110.15
$1.65M
20% of stake
Jan 5 – 610b5-1 plan
Henry E. Pelish
Chief Scientific Officer · sold 5,160 at avg $97.24
502K
5.8% of stake
Jan 5 – 610b5-1 plan
Darlene Noci
Chief Development Officer · sold 7,417 at avg $97.25
721K
11% of stake
Jan 5 – 610b5-1 plan
Deborah Ann Miller
Chief Legal Officer · sold 6,952 at avg $97.26
676K
10% of stake
Jan 5 – 610b5-1 plan
Christopher Durant Turner
Chief Medical Officer · sold 7,417 at avg $97.25
721K
9.3% of stake
Jan 5 – 610b5-1 plan
Alexandra Balcom
Chief Financial Officer · sold 7,417 at avg $97.25
721K
7.0% of stake
Jan 5 – 610b5-1 plan
James Richard Porter
President and CEO · sold 27,433 at avg $97.26
$2.67M
7.8% of stake
Jan 210b5-1 plan
Deborah Ann Miller
Chief Legal Officer · sold 10,000 at avg $100.51
$1.01M
17% of stake
Dec 30, 202510b5-1 plan
Darlene Noci
Chief Development Officer · sold 4,000 at avg $100.04
400K
7.7% of stake
Dec 8, 202510b5-1 plan
Alexandra Balcom
Chief Financial Officer · sold 7,084 at avg $110.32
782K
11% of stake
Nov 28, 202510b5-1 plan
Darlene Noci
Chief Development Officer · sold 4,000 at avg $108.58
434K
7.7% of stake
Nov 24, 202510b5-1 plan
Matthew Shair
Director · sold 7,500 at avg $109.37
820K
0.4% of stake
Nov 24, 2025No plan
James E Flynn
Director · sold 742,574 at avg $95.45
$70.9M
4.1% of stake
Nov 17, 2025 – Nov 18, 202510b5-1 plan
Alexandra Balcom
Chief Financial Officer · sold 20,729 at avg $99.62
$2.07M
25% of stake
Nov 17, 202510b5-1 plan
Deborah Ann Miller
Chief Legal Officer · sold 24,200 at avg $105.50
$2.55M
33% of stake

How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch NUVL, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with NUVL

CompareIntrinsic value

SLNOSoleno Therapeutics Inc

No recent price25

OPKOpko Health Inc.

$1.77+2.91%25

IBIOiBio, Inc.

$0.80-2.44%10

LFVNLifeVantage Corporation

$5.97+3.65%73

PAHCPhibro Animal Health Corporation

$39.43+4.73%57

HOOKHookipa Pharma Inc.

No recent price20

VCNXVaccinex, Inc.

$0.70-1.39%10

PTIXProtagenic Therapeutics, Inc.

$0.65+4.84%20

Held by ETFs

NUVL is in 12 US ETFs. The largest of them, with NUVL's weight in each:

Spot a number that looks wrong? Check it in NUVL's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

2 of 2 free stocks used today

Keep analysing NUVL

Create a free account and get 14 days of Premium: every stock and every tool.

Unlimited stocksQuality, fair value and dividends for 10,000+ stocks
Stock screenerFilter on quality, valuation and dividend safety
Portfolio trackerReal return, dividend calendar and portfolio quality
Editable DCFChange the assumptions and watch fair value move
Compare side by sideUp to 10 stocks in one table
Unlimited alertsPrice, P/E, Quality Score and yield

No card. Moves to Free after, unless you upgrade.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.